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Implementation of medication management services 
at the primary healthcare level – a pilot study
This study employed a mixed-method approach to en-
able the implementation of comprehensive medication 
management (CMM) services in Croatia’s primary care 
setting. Drug therapy problems (DTPs) and factors asso-
ciated with their occurrence were determined in patients 
with chronic diseases from January 2018 to April 2019. 
The pre-implementation stage established the founda-
tions for the early implementation stage, in which the 
practice was set up, the patients’ recruitment initiated 
and various challenges identified. During the study pe-
riod, 86 patients were recruited for CMM provision. 
Overall, 2.8 DTPs (± 1.6) per patient were identified and 
the majority (96.2 %) presented with at least one DTP. 
Multiple regression analysis showed that type 2 diabetic 
patients (p = 0.025) and patients using five or more medi-
cations (p = 0.011) should be prioritized to receive CMM 
services as potentially they have a higher number of 
DTPs, and could, therefore, obtain a greater benefit from 
the service.
Keywords: comprehensive medication management ser-
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Pharmaceuticals are the most common medical intervention and their ability to con-
trol disease and impact overall cost, morbidity, and productivity, when appropriately 
used, is enormous (1, 2). According to the latest OECD publication “Health at a Glance: 
Europe 2018”, pharmaceuticals expenditure, including prescription and over-the-counter 
medications, presented the third largest item of health care spending in the European 
Union (EU) (3). Croatia is among the EU Member States with the highest expenditure on 
medical goods, mainly pharmaceuticals, amounting to 28.5 %, compared to an EU average 
of 18.5 % (3). Moreover, mortality rates from cardiovascular diseases are almost double the 
EU average and mortality rates from lung, breast and colorectal cancer are among the 
highest in the EU, pointing to shortcomings in health care delivery and public health in-
terventions in Croatia (3).
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In addition, a continuous increase in the prevalence of chronic medical conditions is 
expected alongside the accompanying polypharmacy (4). This scenario renders chronic pa-
tients at an increased risk of experiencing drug therapy problems (DTPs), hence adding 
substantial costs to the health care system and exceeding the amount spent on the medica-
tions themselves (5–7).
New approaches are needed at an individual and population level to provide safe and 
effective pharmacotherapy to patients in an ever more complex environment (8). Thus, to en-
sure patients’ optimal medication use and improve their clinical outcomes, comprehensive 
and systematic management of medications is deemed crucial. Comprehensive Medication 
Management (CMM) services (9), officially recognized by the Federal Government of the USA 
in 2003 (MMA 2003) (10), address this problem. The provision of CMM involves a logical and 
patient-centered approach to medication optimization that ensures every medication used by 
a patient is appropriate, effective, safe and convenient to be taken. Almost 30 years have passed 
since Hepler and Strand had defined pharmaceutical care as a practice in which a pharma-
cist-practitioner takes the responsibility for a patient’s drug-related needs by identifying, re-
solving and preventing DTPs (9). Collaborative practice between pharmacists and general 
practitioners (GPs), together with patients’ active participation in the definition of treatment 
regimens, plays an important role in the effectiveness of CMM services (9). Apart from the 
USA, several countries (e.g. Great Britain, Australia, Canada and Brazil) have managed to in-
tegrate CMM services into their existing health care system at the primary care level (11–16). 
In January 2018, CMM services were introduced as a pilot project in the largest county 
health centre in Croatia – Health Centre Zagreb – Centre, thus becoming the first and, at the 
moment, the only health centre in Croatia and South-Eastern Europe providing CMM by 
using the patient care process proposed by Cipolle et al. (9). However, until now little descrip-
tive and in-depth comparative qualitative work has been published to broaden the under-
standing regarding the process of implementation of CMM services. Therefore, the primary 
aim of this study is to describe the newly implemented practice management system of 
CMM services at the county health centre in Croatia. In addition, various studies have 
demonstrated its effectiveness on clinical (14, 15, 17–24), economic (17, 22, 23, 25) and human-
istic outcomes (26, 27). Other studies determined some factors associated with the occur-
rence of DTPs, such as polypharmacy, multimorbidity and age, yet employed methodology 
or clinical settings dissimilar to the present study (28–31). However, to the best of authors’ 
knowledge, until now, no study determined the associated factors of patients with chronic 
diseases at the primary care level as they receive CMM services that follow the theoretical 
framework proposed by Cipolle et al. (9). Therefore, the secondary aim of the present study 
was to describe the DTPs and to determine the factors associated with their occurrence 
among general ambulatory patients receiving CMM services at the primary care level.
EXPERIMENTAL
Study design
In this paper, a mixed-method methodology, involving the use of a combination of 
qualitative and quantitative approaches to data gathering, was employed. The first part 
was a qualitative study that used an action research methodology with the aim of imple-
menting CMM services, a new patient care service in the Croatian primary health-care 
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system, and describing the implementation processes involved. Action research followed 
the procedures proposed by Kurt Lewin (32), its founder, who assumed that human sys-
tems can only be understood and changed if their members take part in this process. 
Considering the complexity involved in implementing a new health service in the Croatian 
health system, such as CMM services, this approach was suitable for the herein present 
study. Within the active research strategy, the first two authors were active in implement-
ing and providing the service, that is, being practitioners, while at the same time they were 
gathering and analysing data, or acting as researchers.
The implementation stages utilized previously published research as a roadmap (33, 34), 
which was adapted to the Croatian reality as needed. Additionally, the previously pro-
posed implementation system assisted the piloting of the initial implementation of CMM 
services through two stages: pre-implementation and early implementation (34). The 
pre-implementation stage encompassed the following components: ensuring a usable 
 innovation (use of a common language for the CMM philosophy of practice and patient 
care process), building an implementation team, developing practitioners’ readiness to 
provide the service, identifying and ensuring essential practice management support 
 (infrastructure necessary to ensure the capacity to implement CMM), assessing fidelity of 
the service and establishing a practice-policy loop.
The second part, the quantitative approach, was a prospective, observational study on 
CMM services provided to ambulatory patients that was conducted from January 2018 to 
April 2019 at the primary care clinic, Health Centre Zagreb – Centre (HCZC), with an aim 
of describing DTPs and determining the factors associated with their occurrence. These 
results are a part of a larger study designed as an open controlled pre- and post-interven-
tion study with a 1-year patient follow-up. Thus, this paper presents a secondary subset 
analysis of trial data evaluating the impact generated by a CMM service in patients with 
chronic health conditions as a primary outcome measure (unpublished to date). 
Setting 
The CMM services outlined in the present study are piloted in an independent coun-
seling unit, Pharmacotherapy counselling service, located in the county health centre, HCZC. 
This is a primary health care institution and the largest health centre in the Republic of 
Croatia with 101 active GPs teams. The HCZC’s CMM service, developed in partnership 
with the University of Zagreb Faculty of Pharmacy and Biochemistry (UoZ) as a part of 
the joint research project, was established in January 2018 to help patients manage their 
chronic health conditions and optimize the therapeutic value of medicines. Until now, this 
is the only health centre in the country providing CMM services at the primary care level 
in Croatia. Two pharmacists from the UoZ Faculty of Pharmacy and Biochemistry facili-
tated the implementation of the CMM services in the health centre by using the same 
standardized patient care process (18). CMM services were provided to patients with 
chronic conditions taking multiple medications, but who were not meeting their therapy 
goals. Based on the pre-defined inclusion criteria, GPs identified patients and referred 
them to the pharmacist. The inclusion criteria were the following: a) patients who have not 
reached or are not maintaining the intended therapy goal, b) patients experiencing adverse 
effects from their medications, c) patients having difficulty understanding and following 
their medication regimen, d) patients in need of preventive therapy, and e) patients fre-
quently readmitted to hospital. The initial assessment lasted 60–90 minutes and the follow-
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up evaluations 30–60 minutes. Alternatively, patients were followed-up by telephone. The 
infrastructure needed for the provision of the service, including the space facilitating the 
delivery of quality service, access to patients, access to the patients’ health care providers 
and administrative support, was ensured by the HCZC. Furthermore, newly implemented 
electronic consultation system (Health.net PRO) (35) at the HCZC enabled GPs to consult 
with both, hospital medical specialists and practising pharmacists providing CMM services, 
thus creating a unique platform for patient referral and care plan sharing. Aside from GPs 
and pharmacists, no other health care professionals were present within this setting.
Data collection
Qualitative data. – Data were collected through semi-structured interviews, group meet-
ings (focus-groups), participant observation, and field journals with descriptions and reflec-
tions on the process of implementing and delivering comprehensive medication manage-
ment services. Semi-structured interviews and group meetings were conducted with GPs 
and other stakeholders (health policy experts and health-system experts) for sixteen months, 
and a total of twenty GPs and three members of the management board of the health centre 
participated in this study.
Both unstructured interviews and group meetings served to introduce the service to 
GPs, but also to study their views on today’s status of the health care system in general, their 
perspectives on medicine use and rational medication use, and the need for introducing 
medication management services in the ambulatory clinic. The group meetings allowed 
discussions regarding the benefits and outcomes of integrating medication management 
services with other existent services, the types of patients that could benefit most from the 
service, the value of the service, and their expectations related to the new service. Moreover, 
practicalities like the structure of a patient’s personal medication plan and communication 
channels between pharmacists and GPs were examined. Since the beginning of the project, 
twenty-five meetings with the Head of the family medicine specialists took place to share 
ideas and updates on the progress of the project, and to create new solutions for the advance-
ment of the service.
To encourage and sustain the reflectivity of the team, discussions between the two 
practitioners-researchers were being held on a weekly basis, and with their trainer, a highly 
experienced researcher, on a monthly basis. Moreover, participant observation involving 
journaling and reflection by the practitioners/researchers occurred during the entire imple-
mentation period to reach an in-depth understanding of experiences, feelings and actions 
practitioners lived through during this time. Pharmacists’ experiences with the patient-caring 
process, descriptions of the events that depicted the project’s process, ideas for project develop-
ment and the vision for the CMM services in the future including the remuneration options, 
were being kept.
As abovementioned, in order to minimise research bias and enhance the validity of the 
results, triangulation of different methods of data collection and researcher reflexivity was 
employed. As previously emphasized, once a proposition has been confirmed by more than 
one independent measurement process, the level of uncertainty surrounding it is reduced (36). 
Quantitative data. – Data was collected from CMM interventions with patients which ran 
from January 2018 to April 2019. Patients were eligible for the participation if they were aged 
18 years or more with at least one regular prescription medication and were admitted fol-
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lowing referral by their general practitioner or self-referral. Data were retrieved by a careful 
review of paper and electronic medical records, and through the interview with the patient, 
or a patient’s family member or a caregiver, if needed. Subsequently, the data were entered 
into the CMM documentation system that stored all the patients’ records. The extracted data 
contained the following fields: patients’ demographics, current and previous medical con-
ditions, number of medications taken, history of drug allergy and adverse drug reactions, 
number of CMM consultations, types of drug therapy problems identified and addressed, 
types of interventions implemented to resolve drug therapy problems and change in pa-
tients’ clinical status. Prescription medications for chronic conditions and all active over- 
-the-counter (OTC) medications, as well as herbal remedies, supplements and medications 
used for a limited period of time were included in the analysis. The principal diagnosis and 
comorbidities were coded according to the International Classification of Diseases (ICD-10 
Version: 2016) and Anatomical Therapeutic Chemical (ATC) Classification codes were used 
to analyse the drug therapy. Patients using methadone and other patients with addiction 
problems, mental and behavioural disorders due to psychoactive substance use and patients 
with cognitive impairment were not deemed eligible and were thus excluded from the study. 
The study protocol was approved by the Health Centre’s Ethics Committee and the Ethics 
Committee of the University of Zagreb Faculty of Pharmacy and Biochemistry. This study 
followed guidelines of the Declaration of Helsinki and Tokyo. 
The patient care process
The patient care service employed in this study, namely CMM service, followed the 
philosophy and the standardized patient care process proposed by Cipolle et al. (9). Each 
CMM encounter was based on the rational decision-making process referred to as the 
Pharmacotherapy Workup (9). This process represents cognitive work taking place in the 
* Type of patient’s referral to Pharmacotherapy counselling service: GP referral; Self-referral; Other (family/friend 
recommendation, specialist referral).
Fig. 1. Workflow diagram of CMM services.
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mind of the practitioner and is used to identify, resolve, and prevent DTPs, establish therapy 
goals, select interventions and evaluate actual outcomes. Identifying a DTP required the 
practitioner to establish an association between the patient’s medical condition and the 
patient’s pharmacotherapy with the purpose of determining whether the patient’s drug-re-
lated needs were being met. Patients’ DTPs identified and addressed by CMM pharmacists 
were categorized into seven groups (Appendix A) and always assessed in the same sys-
tematic order; first, the appropriateness of the drug therapy, followed by the effectiveness 
of drug regimen, safety and at the last place, adherence. Moreover, this standardized pro-
cess is implemented in a patient-centred manner, which takes the patient’s unique circum-
stances, needs and expectations into consideration. The workflow of the patient care pro-
cess specific for Croatian primary care level is shown in Fig. 1.
Study variables and data analysis
The independent variables included demographic characteristics of a patient (age, sex 
and employment status), anthropometric and clinical (number of diseases, number of 
drugs used, diagnosis of cardiovascular disease, hypertension, dyslipidaemia or diabetes, 
hospitalization and emergency department visit recorded in the previous year) and smok-
ing status. The sum of the DTPs detected during the first and second consultation was 
dichotomized (0–2 DTP; ≥ 3 DTP) and defined as the dependent variable. Quantitative 
variables were described according to their mean, standard deviation, median and inter-
quartile range, while categorical variables were shown as frequency and percentage. 
Pearson’s Chi-squared test or Fisher’s exact test were used to assess univariate analy-
ses between the independent variables and the DTP presence. Independent variables with 
p < 0.15 in the univariate analyses were included in a multivariable logistic regression 
model to identify factors associated with the dependent variable. Taking into consideration 
that the univariate analysis represents the initial step to the associated factors analysis, the 
higher p < value (p < 0.15) was selected to ensure that no important variable was left outside 
the final and multivariate analysis. To evaluate the goodness of fit of the model, the Hos-
mer-Lemeshow test was used and a likelihood ratio test was used to compare the models. 
A p < 0.05 was considered statistically significant in all analyses. All of the data were ana-
lysed with the IBM SPSS software, version 22.0 (SPSS Inc, Chicago, SAD).
RESULTS AND DISCUSSION
Qualitative results
Piloting the implementation of the CMM services in the county health centre. – The following 
description depicts observations, understandings and experiences of implementing CMM 
services at the primary care clinic, HCZC in Zagreb, Croatia for the first time. 
Pre-implementation (preparation). – Three years prior to the commencement of the pilot 
project, an implementation team of five members was established, each member with a 
unique role and set of skills in the areas of pharmacy practice, clinical pharmacy, quality 
improvement, primary care, health systems in transition and health care reforms. The 
team assembled periodically to discuss and set the grounds for the implementation of the 
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new service. Firstly, the suitability of various primary care practice sites was explored to 
determine whether the structural (private consultation room, documentation system, ac-
cess to evidence-based information) and system-level support systems (support of clinic 
leadership and primary care physicians) were in place to facilitate the successful imple-
mentation of the CMM services. To ascertain that, a series of interviews with health centres 
managers and GPs across multiple study sites were conducted over a period of one year, 
until an agreement with an interested health centre was reached and the availability of the 
practice management infrastructure was assured.
Furthermore, the identification of an ‘in-house’ key person interested in initiating this 
innovation, in this case, the Head of family medicine specialists, was of paramount impor-
tance, as he facilitated the introduction of the new service into the health centre. Utilizing 
the vast scientific literature already published in different countries about the impact of 
CMM services (18, 19, 21, 24), the perceived need and the benefits of this innovation were 
communicated with the Director of Health Care Centre and the Head of the family medicine 
specialists over four group meetings during a two-month period. Openness and eagerness 
of the management board to allow the piloting of the new service was seen as the rate-increasing 
step for the outset of the project.
Although this study describes a pilot project, and not a full-service implementation 
(remuneration was not ensured for practicing pharmacists), fidelity measures were under-
taken through a series of steps. Bearing in mind the importance of ensuring a usable inno-
vation, it was made sure that both pharmacists providing the service spoke a common lan-
guage and delivered the same standards of care, which was achieved through a shared 
commitment to the philosophy of practice that underlies the CMM patient care process (9).
Furthermore, to ensure both pharmacists at the primary care clinic were prepared to 
engage in the implementation of the service, several learning strategies were employed. 
During a three-month doctoral internship at the Centre for Pharmaceutical Care Studies, 
Federal University of Minas Gerais in Belo Horizonte, Brazil, the philosophy of pharmaceu-
tical care practice and the core elements of CMM services were mastered by the younger 
researcher (PhD student). Learning resources, such as documents overviewing CMM pa-
tient care process and the philosophy of practice (37), on-line training, coaching calls and 
access to real-life practice to provide a forum for sharing lessons learned, were utilised to 
equip both pharmacists with the skills and knowledge necessary to successfully commence 
with the implementation process. Additionally, a relationship with a highly experienced 
researcher, practitioner and trainer was established and maintained throughout the project. 
The trainer’s continuous assistance and coaching provided through regular telephone meet-
ings was invaluable for the piloting process. Besides the required transformation in pharma-
cists’ attitudes and behaviours, CMM services are a multi-layered service requiring a pro-
found knowledge-base in pharmacotherapy. Hence, a connection was established with 
several medical specialists who provided external support by covering multiple content 
areas (e.g. endocrinology (N = 2), cardiology (N = 1), pulmonology (N = 1), ophthalmology (N 
= 1) and nephrology (N = 1)). Finally, to keep pace with the ever-evolving field of pharmaco-
therapy, evidence-based literature (38–40) and clinical decision support systems (41) were 
consulted. Additionally, lecture-based courses covering various pharmacotherapy topics 
were continuously attended. 
Subsequently, establishing and standardizing workflow and a management system 
unique to this specific health centre was a challenging assignment for the team members. 
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Three group meetings and two working sessions were carried out for both implementation 
team members and external consultants recruited to provide support. This work resulted in 
the development of the document describing the work process flow, namely GP-pharma-
cist-patient communication, the process of referring patients to a pharmacist, various chan-
nels of GP-pharmacist communication, the layout of patients’ output documents and other 
aspects of the practice management system. Components of the practice management sys-
tem adapted to Croatian primary health care setting are shown in Fig. 2.
Finally, the team engaged in sharing learnings about the implementation process 
through various communication strategies: publishing in peer-reviewed research manu-
scripts, presenting at conferences and by engaging in discussions with key stakeholders. 
This period was sufficient to gain a deeper understanding of the philosophy, patient care 
process and practice management system of pharmaceutical care practice. Altogether, dur-
ing this period, visions and ideas were shared between the implementation team, challenges 
were identified, and potential solutions scrutinized. It is strongly believed by the authors of 
this paper that such a thorough and lengthy preparation laid down the grounds for the 
forthcoming piloting stage, namely early implementation of CMM services.
Early implementation. – Once all the pre-requirements for CMM implementation were 
in place, the Pharmacotherapy counselling service at the HCZC initiated its work. To reach 
as many GPs as possible, at the outset of the project an email inviting to engage in the 
CMM services was sent to all GPs (N = 101), leaflets with all the necessary information on 
CMM services were printed and distributed across the HCZC facilities, a new website was 
created and a public health campaign with a stand dedicated to CMM services was organ-
ized. Thus, all the information on the newly commenced service was made public and 
widely available. Additionally, a practicing pharmacist personally visited twenty GPs lo-
cated in the same building as the Pharmacotherapy counselling service to prompt them to 
engage in the CMM initiative. Despite all of this effort, during the first six months, the 
response and active engagement of the family medicine specialists was rather poor, how-
ever, it increased towards the end of the first year. Regardless of the fact that pharmacists 
did not share the office space with other health-care providers and were thus not highly 
visible on a daily basis, the recruitment of patients for the CMM services almost exclusively 
occurred through referral by general practitioners or self-referral. Hence, the predomi-
nance of the active search of patients by the pharmacist, as previously noted (42), was not 
encountered in the present study. Nevertheless, as previously described in the literature 
(43), it can be assumed that patient recruitment and acceptance of the service would have 
been more prominent, had the pharmacists shared the working space with GPs, and thus 
had been more visible. To allow for the standardisation of the patient care process, and 
consistency of CMM implementation, both pharmacists were present during all patient 
encounters. Thus, all uncertainties were immediately discussed and a consensus, regard-
ing the identification of DTPs and proposed interventions, was reached.
During this stage, the team faced several challenges. One of the biggest challenges was 
the unawareness of medical providers of the existence of the new service at the health centre 
or the scope and benefits of such service regardless of the fact that they were informed, 
which resulted in their lack of involvement. To improve GPs’ active engagement, various 
meetings and events were organized, ranging from presenting the CMM concept at GPs’ 
monthly assemblies at the health centre in front of a large group of GPs to multiple one-on-
-one meetings to explain what CMM stands for, the potential benefit of the service to patients 
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and GPs, and the steps for engaging the patient into the service. Overall, twenty one-on-one 
meetings with GPs were held within the first sixteen months of the piloting, and the re-
sponse rate of GP’s actually adopting this innovation was still rather low. Out of the total 
number of informed GPs (N = 101), only four have fully embraced the service (3.9 %) and nine 
have sporadically engaged with the service, that is referred 2–3 patients altogether.
Importantly, the Head of family medicine specialists was appointed by the implemen-
tation team as the ‘key person’ (‘champion’) with the role to showcase success and share the 
progress of the CMM initiative with clinic leadership and practicing GPs. Even though hav-
ing the champion GP was very helpful, this process of getting acceptance in the clinic was 
found extremely demanding, time-consuming and wearing, requiring various sets of skills, 
mainly to do with negotiating the introduction of a new service within an already estab-
lished rigid system. Without conducting a deeper qualitative study on the underlying rea-
sons for GPs’ lack of involvement, the authors suspect that lack of time, lack of interest, for-
getfulness, resistance to change as well as their frequent rotations between multiple practice 
sites were the main factors contributing to poor response rate. The highest success was ac-
complished with younger GPs, particularly those with less than 5 years of professional ex-
perience in primary health care (N = 3 out of four, 75 %).
In conclusion, the action research stage of this study illustrates both pre-implementa-
tion and early implementation stages of CMM in a primary care practice with all the chal-
lenges that we came across and that needed to be taken into consideration while introduc-
ing the CMM service. Moreover, it reflects other experiences and learnings from the use of 
the implementation system utilized for the purpose of this initiative (early implementa-
tion) (34, 43). 
Quantitative results
Data were prospectively collected from 86 patients, of which 54 (62.8 %) were female. 
Patients’ median age (overall range) was 70.5 (32–87) years, with 73.3 % (N = 63) being 65 
years or older. The median number (overall range) of medications per patient was 8 (2–19) 
and polypharmacy (more than 4 medications used) was recorded in 68 (79.1 %) patients. 
Cardiovascular medications were the most frequently prescribed group of medications 
(42.5 %). Accordingly, diseases of the circulatory system were the most prevalent condi-
tions (42.5 %), with hypertension as the most commonly presenting condition (82.6 %). 
Overall, the median number (overall range) of medical conditions per patient was 5 (1–11), 
and 54.7 % had five or more comorbidities. Detailed study sample characteristics are 
shown in Table I. 
During the initial two visits, overall 241 DTPs were identified with an average of 2.8 
DTPs (± 1.6) per patient. At least one DTP was identified in 81 (96.2 %) patients, of which 
30.2 % had 4 or more DTPs. The most prevalent DTP was “Needs additional therapy” (26.1 
%), with “Untreated condition” being the most common cause. The second most frequent 
DTP category was “Dosage too low” (24.5 %), followed by “Unnecessary drug therapy” 
(12.4 %) and “Dosage too high” (11.6 %). Only 5.0 % of identified DTPs were related to 
non-adherence. Appendix A lists the prevalence of DTP categories, along with its causes 
and the most common examples. The medications most frequently associated with DTPs 
were pantoprazole, statins, and bisoprolol (Table II).
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Table I. Study sample characteristics
Characteristic Study sample (N = 86)




Smoking status, N (%) Yes 11 (12.8)
Medications used at the initial visit, N 710
Medications used per patient at the initial visit, median (range) 8 (2–19)
Use of cardiovascular system medications, N (%) (ATC class C) 
Use of alimentary tract and metabolism system medications, N (%) (ATC class A) 




Diagnoses at the initial visit, N 361
Diagnoses per patient, median (range) 4 (1–9)
Most frequent diagnosis-related groups, N (%)
Diseases of the circulatory system (ICD-10 I00-I99), N (%) 
Endocrine, nutritional and metabolic diseases (ICD-10 E00-E99), N (%) 




Table II. The most common drug therapy problems associated with medications
Medication Frequency of drug therapy problems, N (%)
The most common drug therapy problem 
category, N (%)
Pantoprazole 14 (5.8) Unnecessary drug therapy, 5 (2.1)
Statins 13 (5.4) Needs additional therapy, 7 (2.9)
Bisoprolol 13 (5.4) Dosage too low, 6 (2.5)
Amlodipine 9 (3.7) Needs additional therapy, 3 (1.2)
Ramipril 9 (3.7) Dosage too low, 2 (0.8)
Perindopril 7 (2.9) Needs additional therapy, 2 (0.8)
Furosemide 7 (2.9) Dosage too low, 2 (0.8)
Metformin 7 (2.9) Dosage too low, 2 (0.8)
Moxonidine 7 (2.9) Needs additional therapy, 2 (0.8)
Diazepam 6 (2.5) Unnecessary drug therapy, 3 (1.2)
According to the univariate analysis, several factors showed significant association 
with the identification of three or more DTPs: age (p = 0.010), employment status (p = 0.016), 
number of comorbidities (p = 0.001), polypharmacy (p = 0.000), hospitalizations in previous 
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year (p = 0.107), hypertension (p = 0.029), type 2 diabetes (p = 0.010) and dyslipidaemia (p = 
0.001) (Table III). Multivariate analysis showed that patients with polypharmacy were 8.86 
times more likely to have three or more DTPs than the patients using 4 or less medications 
(p = 0.011). In addition, type 2 diabetes was the second most significant factor associated 
with the identification of three or more DTPs (p = 0.025). Detailed results of multivariable 
logistic regression are shown in Table IV.
CMM is a patient-centred clinical service provided by specially educated pharmacists 
in collaboration with general practitioners and other health care providers, designed to 
optimize patients’ drug-therapy and improve clinical outcomes (1). However, CMM services 
are still fairly novel at the primary care level and, for that reason, are generally not embedded 
in health care systems across Europe (9). Moreover, due to implementation varia bility 
Table III. Univariate analysis of factors associated with the DTP occurrence among patients with chronic 








































































































































a OR – odds ratio; b CI – confidence interval
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across various clinical settings, patient types and practitioners, delivery of CMM services 
still appears to be inconsistent and its implementation process relatively poorly documented 
(34). Therefore, this manuscript innovates as it provides an in-depth description of the 
process of the initial implementation of CMM services at a primary care practice site, thus 
adding important knowledge about both the process of implementation of pharmacist-led 
care delivery models and the most prevalent drug-therapy problems experienced by Croatian 
patients in the real world.
To the best of authors’ knowledge, this is the first study providing an exhaustive research- 
-based depiction of the process of the initial implementation of CMM in Croatia and Europe. 
The narrative provided here presents the footsteps and strategies to assist willing practitioners 
to successfully introduce this new service in health care systems. Even more, this study 
 describes some of the topics that need to be reflected upon to prepare a ‘new pharmacist’, a 
professional with a completely different set of competencies required for the assimilation of 
a new professional practice, pharmaceutical care practice, and the provision of patient-centred 
services (1, 9, 44). Namely, the traditional education provided at most universities worldwide 
does not prepare pharmacists to work as patient-centred health-care providers, neither 
 professionals with competencies to work as a part of a multidisciplinary team. Although 
graduate curricula highlight the importance of inter-disciplinarity, the science-practice gap 
still remains unabridged (44, 45). 
As the project unfolded, it became clear that the responsibilities and functions of pharma-
ceutical care practitioners are very different from those of community pharmacists. Action 
Table IV. Multivariate analysis of factors associated with the DTP occurrence among patients with chronic 
diseases receiving CMM services
Variable ORa (95 % CIb) p-value
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research became a valuable mechanism that instigated the team or pharmacists/researchers 
to think about its responsibilities within the context of primary care outside the community 
pharmacy setting. To provide CMM services, pharmacists had to accept co-responsibility for 
patients’ clinical outcomes, thus becoming like the other members of the health care team, 
and finally to recreate their identity as patient-centred healthcare professionals. As already 
confirmed in previous research (16), pharmacists can feel fearful and insecure to assume 
new roles that imply being held accountable for patients’ clinical outcomes. As stressed by 
Rosenthal et al. (46), staying in one’s own familiar environment and avoiding leaving one’s 
comfort zone is ingrained in pharmacist’s culture. In addition, as revealed in other studies 
(16, 47–49), action research encouraged individual and group reflections on new circum-
stances and allowed for the conception of the most fitting organizational model for an efficient 
implementation of CMM services.
This study showed how challenging it is to introduce a new service into a rigid and 
already established health care system. As the project progressed, several challenges were 
encountered: a) resistance of GPs to embrace the new service available at their premises; b) 
lack of experience of both practising pharmacists in establishing collaboration with GPs and 
working in a multidisciplinary team; and c) defining the new work process necessary to 
provide a standardized and reproducible service. The latter two were mastered throughout 
the course of the project, while the first one still remains a challenge for researchers/practi-
tioners. Finally, the initial implementation of the pharmacy service demanded major work 
as new collaborative channels with GPs were initiated and, consequently profound transfor-
mation in pharmacists’ role. Again, the utilized research methodology became an excellent 
approach that allowed change to occur.
Moreover, this is the first Croatian study that evaluated the incidence and type of DTPs 
in ambulatory patients, thus providing insights regarding the types of medication problems 
patients experience at the primary care level in Croatia. The high number of patients with one 
or more identified DTPs was similar to the rates noted in previous research (9, 17, 18, 24), 
demonstrating how CMM services add value to the current standard of care patients are rece-
iving in Croatian health care system. Moreover, consistent with previous evaluations of CMM 
practices, the two most common DTPs were “Needs additional therapy” and “Dosage too 
low“ (17, 18, 23), suggesting that the major DTP in present population is the underutilization 
of effective medications. This finding is quite contrary to the assumption that pharmacists’ 
major role is to reduce the number of medications and medication costs for patients. As 
showed by Isetts et al. (23), the economic impact of CMM services is mainly due to a significant 
decrease in the total costs of health care, instead of a decrease in medication costs. By helping 
patients to reach their therapeutic goals, CMM pharmacists can enhance health outcomes, 
and thus impacting the overwhelming costs associated with bad outcomes. In addition, 
 “Adherence” was one of the least commonly presented DTPs. Although pharmacy practice 
tends to focus on patients’ adherence, low prevalence of non-adherence problems in the  current 
and previous studies (9, 18) point to the importance of following the rational  decision-making 
process proposed by pharmaceutical care practice, which means firstly  ensuring that 
every medication is appropriate, effective and safe for a specific patient, and only in the end 
guaran te eing that the patient is willing and able to take their medications (50).
This study is one of the first research to have determined the factors associated with the 
occurrence of DTPs at the primary care level (24), by employing the theoretical framework 
proposed by Cipolle et al. Moreover, it appears to be the first study to have established 
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DTP-associated factors among general ambulatory patients, by using the aforementioned 
methodology. In line with published evidence (24, 28, 29), polymedicated patients were more 
likely to have a higher number of DTPs. The second characteristic most strongly associated 
with the occurrence of three or more DTPs was type 2 diabetes. Both of the above-mentioned 
factors associated with the DTP occurrence could be used as screening criteria for patients’ 
referral to CMM services, since those types of patients potentially have higher drug-related 
needs and therefore, could benefit more from the service. Consistently, results of this study 
provide information to better tailor the training of practitioners, so that encountered DTPs 
could be more efficiently identified, resolved and prevented.
CONCLUSIONS
The action research methodology enabled an effective approach to introducing a new 
pharmacist-led service in the Croatian primary health care, as well as detecting the chal-
lenges encountered throughout the process of the initial implementation of CMM services. 
The challenges encountered should be tackled for full implementation of CMM services 
and need to be taken into consideration in the future implementation of this service in 
other health care settings. Additionally, a deeper understanding of work processes and 
resources needed for the initial implementation of CMM were of paramount importance 
for a successful introduction of CMM within a primary care setting.
The high incidence of DTPs identified among patients with chronic conditions at the 
primary care level indicates the need for pharmaceutical care services in this population. 
Type 2 diabetic patients and patients using five or more medications should be prioritized 
for CMM services as potentially they could have a higher number of drug therapy prob-
lems and could, therefore, have a greater benefit from the service. The analysis provided 
in this study refers to the need for tailoring a targeted education for practitioners, so that 
encountered DTPs could be more efficiently identified, resolved and prevented. Further 
research is needed to establish the impact of provided care on clinical outcomes in the 
Croatian health care setting.
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 th
e 
fe
ar
 o
f p
ot
en
tia
l s
id
e 
eff
ec
ts
2 
(0
.8
)
7.5
.  S
im
pl
if
yi
ng
 d
ru
g 
ad
m
in
is
tr
at
io
n
4 
(1
.7
)
D
ai
ly
 u
se
 o
f v
ita
m
in
 D
 d
ro
ps
 s
w
itc
he
d 
fo
r o
nc
e 
pe
r m
on
th
 v
ita
m
in
 D
 a
m
pu
le
s 
fo
r 
os
te
op
or
os
is
 tr
ea
tm
en
t
1 
(0
.4
)
A
C
EI
 –
 a
ng
io
te
ns
in
-c
on
ve
rt
in
g 
en
zy
m
e 
in
hi
bi
to
r; 
A
F 
– 
at
ri
al
 fi
br
ill
at
io
n;
 A
P 
– 
an
gi
na
 p
ec
to
ri
s; 
A
R
B 
– 
an
gi
ot
en
si
n 
re
ce
pt
or
 b
lo
ck
er
; A
SA
 –
 a
ce
ty
ls
al
ic
yl
ic
 a
ci
d;
 B
B 
– 
be
ta
 b
lo
ck
er
; B
M
I –
 b
od
y 
m
as
s 
in
de
x;
 B
PH
 –
 b
en
ig
n 
pr
os
ta
tic
 h
yp
er
pl
as
ia
; C
C
B 
– 
ca
lc
iu
m
 c
ha
nn
el
 b
lo
ck
er
; C
O
PD
 –
 c
hr
on
ic
 o
bs
tr
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e;
 C
V
I –
 
ce
re
br
ov
as
cu
la
r i
ns
ul
t; 
D
M
2 
– 
ty
pe
 2
 d
ia
be
te
s 
m
el
lit
us
; E
C
G
 –
 e
le
ct
ro
ca
rd
io
gr
am
; e
G
FR
 –
 e
st
im
at
ed
 g
lo
m
er
ul
ar
 fi
ltr
at
io
n 
ra
te
; G
ER
D
 –
 g
as
tr
oe
so
ph
ag
ea
l r
efl
ux
 d
is
-
ea
se
; H
bA
1c
 –
 g
ly
ca
te
d 
ha
em
og
lo
bi
n 
A
1c
; H
F 
– 
he
ar
t f
ai
lu
re
; I
N
R 
– 
in
te
rn
at
io
na
l r
at
io
; I
SH
 –
 is
ol
at
ed
 s
ys
to
lic
 h
yp
er
te
ns
io
n;
 I
SM
N
 –
 is
os
or
bi
de
 m
on
on
itr
at
e;
 I
M
 
– 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 N
SA
ID
s 
– 
no
ns
te
ro
id
al
 a
nt
i-i
nfl
am
m
at
or
y 
dr
ug
s; 
PP
Is
 –
 p
ro
to
n 
pu
m
p 
in
hi
bi
to
rs
.
